Skip to main content

College of
Health Sciences

Maya Lichtenstein, MD
Geisinger Memory and Cognition Program
620 Baltimore Dr.
Wilkes-Barre, PA 18711

Phone: 570-808-7200
View Google Scholar Profile

Maya Lichtenstein, MD

Research Interests

Dr. Maya Lichtenstein’s research interests include dementia and neurocognitive disorders.

Recent Publications

  • Reuben DB, Gill TM, Stevens A, Williamson J, Volpi E, Lichtenstein M, Jennings LA, Tan Z, Evertson L, Bass D, Weitzman L, Carnie M, Wilson N, Araujo K, Charpentier P, Meng C, Greene EJ, Dziura J, Liu J, Unger E, Yang M, Currie K, Lenoir KM, Green AS, Abraham S, Vernon A, Samper-Ternent R, Raji M, Hirst RM, Galloway R, Finney GR, Ladd I, Rahm AK, Borek P, Peduzzi P. D-CARE: The Dementia Care Study: Design of a Pragmatic Trial of the Effectiveness and Cost Effectiveness of Health System-Based Versus Community-Based Dementia Care Versus Usual Dementia Care. J Am Geriatr Soc. 2020 Sep 19. doi: 10.1111/jgs.16862. Epub ahead of print. PMID: 32949145.
  • Venditto JG, Bender E, Lichtenstein ML. Psychosis in a middle-aged woman: a case of presenilin 1 p.Gly206Ala Alzheimer’s disease. Neurology Clinical Practice. Aug 2020, DOI:
  • Harner MK, Lichtenstein ML, Farrell M, Dietterich TE, Filmyer DM, Bruno LM, Biondi TF, Crowley JJ, Lazaro-Munoz G, Stowe R, Shaughnessy RA, Berg JS, Szatkiewicz J, Sullivan PF, Josiassen RC. Treatment-resistant psychotic symptoms and early-onset dementia: A case report of the 3q29 deletion syndrome. Schizophrenia Research. 2020; 224; 195-197
  • Farrell M, Lichtenstein M, Harner MK et al. Treatment-resistant psychotic symptoms and the 15q11.2 BP1–BP2 (Burnside-Butler) deletion syndrome: case report and review of the literature. Transl Psychiatry 10, 42 (2020).
  • Adduru V, Baum SA, Zhang C, Helguera M, Zand R, Lichtenstein M, Griessenauer CJ, Michael AM. A Method to Estimate Brain Volume from Head CT Images and Application to Detect Brain Atrophy in Alzheimer Disease. American Journal of Neuroradiology January 2020, DOI:
  • Lichtenstein ML, Fallah N, Mudge B, Hsiung GRY, Foti D, Beattie BL, Feldman HH. 16 Year Survival of the Canadian Collaborative Cohort of Related Dementias. Can J Neurol Sci 2018; 7; 1-8
  • Farrell M, Lichtenstein ML, Crowley JJ, Filmyer D, Lázaro-Muñoz G, Shaughnessy R, Mackenzie I, Hirsch-Reinshagen V, Stowe R, Evans J, Berg J, Szatkiewicz J, Josiassen R, Sullivan PF. Developmental delay, treatment-resistant schizophrenia, and early-onset dementia in a man with 22q11 deletion syndrome and Huntington’s Disease. Am J Psychiatry 2018; 175(5); 400-407
  • Lichtenstein ML, Dwosh E, Roy Chowdhury A, Farrer MJ, McKenzie MB, Guella I, Evans DM, Nygaard HB, Shewchuk JR, Hayden S, Barton JJS, Feldman HH. Neurobehavioral Characterization of Adult Onset Alexander Disease: A Family Study. Neurology Clinical Practice. Published online before print March 24, 2017doi:
  • Sterling NW, Lichtenstein M, Lee, E-Y, Lewis MM, Evans A, Eslinger PJ, Du G, Gao X, Chen H, Kong L, and Huang X. Higher plasma LDL-cholesterol is associated with preserved executive function in Parkinson’s disease. Aging and Disease 2016; 7(4); 237-245.
  • Huang X, Alonso A, Guo X, Umbach DM, Lichtenstein ML, Ballantyne CM, Mailman RB, Mosley TH, Chen H. Statins, plasma cholesterol and risk of Parkinson’s disease: a prospective study. Movement Disorders 2015: 30(4); 552-559.


  • Sackler School of Medicine, Doctor of Medicine, 2010
  • The Milton S. Hershey Medical Center, Residency, 2014
  • University of British Columbia, Fellowship, 2016
Content from General Links with modal content